

Stromedix Awarded Grant Under the Qualifying Therapeutic Discovery Project Program

CAMBRIDGE MA, November 2, 2010 – Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, today announced it has received a grant from the Qualifying Therapeutic Discovery Project (QTDP) program, enacted as part of the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148). The grants are awarded to therapeutic discovery projects that show a reasonable potential to (a) result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions, (b) reduce the long-term growth of health care costs in the United States, or (c) significantly advance the goal of curing cancer within 30 years.

Stromedix received a grant in support of STX-100, a humanized monoclonal antibody to integrin $\alpha v \beta 6$, in development for fibrotic diseases such as idiopathic pulmonary fibrosis and chronic allograft dysfunction in kidney transplant patients.

About Stromedix

Stromedix is a privately held biotechnology company based in Cambridge, Massachusetts, focused on innovative therapies for fibrotic organ failure. Investors in Stromedix include Atlas Venture, New Leaf Venture Partners, Frazier Healthcare Ventures, Bessemer Venture Partners and Red Abbey Venture Partners. Biogen Idec is also a shareholder. For more information on Stromedix, please visit <http://www.stromedix.com>.

CONTACT

Stromedix:
Michael Gilman, Ph.D., (617) 674 8402
Chief Executive Officer
michael.gilman@stromedix.com

Paul Kidwell (Media)
Suda Communications LLC
(617) 296 3854

###